跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
prodrug 2
首页
药物
prodrug 2
prodrug 2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US 7435833 B2
申请人: ABBOTT LAB
优先权: 2006
CN
EP
US
6 件公开
CN 101415675 A
申请人: ABBOTT LAB
优先权: 2006
CN
beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
US 7186700 B2
申请人: IDENIX PHARMACEUTICALS INC
优先权: 2003
US
6 件公开
Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
US 12649754 B2
申请人: UCB BIOPHARMA SRL
优先权: 2020
CN
EP
US
WO
5 件公开
DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS
EP 4568949 A1
申请人: ITALFARMACO SPA
优先权: 2022
CN
EP
US
WO
4 件公开
Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease
US 7132433 B2
申请人: AVENTIS PHARMA INC
优先权: 2001
US
4 件公开
Prodrugs activated by plasmin and their use in cancer chemotherapy
US 7402556 B2
申请人: MEDAREX INC
优先权: 2003
US
4 件公开
PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE
US 2014051666 A1
申请人: AFFINIUM PHARM INC
优先权: 2013
US
4 件公开
CYCLOPROPANE FATTY ACID MODULATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
EP 4561979 A4
申请人: UNIV CALIFORNIA
优先权: 2022
EP
US
WO
3 件公开
PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER
EP 4577211 A4
申请人: UNIV WAKE FOREST HEALTH SCIENCES
优先权: 2022
CN
EP
US
3 件公开
SOLID DOSAGE FORM OF A SMALL MOLECULE ANTIVIRAL AND USES THEREOF
EP 4750460 A2
申请人: MERCK SHARP & DOHME LLC
优先权: 2023
CN
EP
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈
